Octapharma: all 71 studies

Page 1 of 1. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.

• Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent InfectionsRecruitingNCT07220915Phase 3
• Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema AttacksRecruitingNCT06361537Phase 3
• Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary BypassRecruitingNCT06096116Phase 3
• Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for SurgeryRecruitingNCT05936580Phase 4
• Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis StudyRecruitingNCT05935358Phase 4
• Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) PatientsRecruitingNCT04929236Phase 3
• Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or DeliveryRecruitingNCT04918173Phase 3
• Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A PatientsRecruitingNCT03695978
• Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac SurgeryCompletedNCT05523297Phase 3Results posted
• Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of AgeCompletedNCT04953884Phase 3Results posted
• Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)CompletedNCT04508530Phase 3Results posted
• Octagam 10% Therapy in COVID-19 Patients With Severe Disease ProgressionCompletedNCT04400058Phase 3Results posted
• Bleeding Incidence in VWD Patients Undergoing On-Demand TreatmentCompletedNCT04053699Results posted
• Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWDCompletedNCT04052698Phase 3Results posted
• Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia ATerminatedNCT04046848Phase 1/2Results posted
• Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency DiseasesCompletedNCT03988426Phase 3Results posted
• Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency DiseasesCompletedNCT03939533Phase 3Results posted
• CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIALCompletedNCT03907241Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)TerminatedNCT03866798Phase 4Results posted
• Study Evaluating Efficacy and Safety of Octanorm in Patients With DermatomyositisTerminatedNCT03686969Phase 3Results posted
• Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia ACompletedNCT03376516Phase 3Results posted
• Immune Tolerance Induction in Haemophilia A Patients Using Wilate or NuwiqTerminatedNCT03344003Results posted
• Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQCompletedNCT02962765Results posted
• Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia ACompletedNCT02954575Phase 3Results posted
• Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.CompletedNCT02740335Phase 3Results posted
• Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)CompletedNCT02728752Phase 3Results posted
• Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) NeuropathyCompletedNCT02638207Phase 3Results posted
• Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin in Paediatric Subjects With Fibrinogen DeficiencyCompletedNCT02408484Phase 3Results posted
• Non-Interventional Study on the Tolerability and Efficacy of IVIGCompletedNCT02303093Results posted
• Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After SurgeryCompletedNCT02267226Phase 3Results posted
• Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia ACompletedNCT02256917Phase 3Results posted
• Octaplas Pediatric Plasma Replacement TrialCompletedNCT02050841Phase 4Results posted
• Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIIICompletedNCT01992549Phase 3Results posted
• Octaplas Pediatric Plasma Exchange TrialCompletedNCT01938378Phase 4Results posted
• Study of Octanorm Subcutaneous IG in Patients With PIDCompletedNCT01888484Phase 3Results posted
• Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia ACompletedNCT01863758Phase 3Results posted
• Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated PatientsCompletedNCT01712438Phase 3Results posted
• Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand DiseaseCompletedNCT01602419Results posted
• Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/RiastapCompletedNCT01575756Phase 2Results posted
• Wilate in Subjects With Von Willebrand Disease Who Undergo SurgeryCompletedNCT01365546Phase 3Results posted
• Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune ThrombocytopeniaCompletedNCT01349790Phase 3Results posted
• Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)CompletedNCT01341912Phase 3Results posted
• High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)CompletedNCT01313507Phase 3Results posted
• Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia ACompletedNCT01125813Phase 3Results posted
• A Trial to Investigate the Relative Efficacy, Safety, and Tolerability of Octaplas LG Versus Octaplas SDCompletedNCT01063595Phase 1Results posted
• A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency DiseasesCompletedNCT01012323Phase 3Results posted
• Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia ACompletedNCT00989196Phase 2Results posted
• Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's DiseaseCompletedNCT00812565Phase 2Results posted
• Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency DiseasesTerminatedNCT00811174Phase 3Results posted
• Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive ProceduresCompletedNCT00618098Phase 3Results posted
• Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in AdultsCompletedNCT00426270Phase 3Results posted
• Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive ProcedureActive, not recruitingNCT06429787
• Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa InhibitorTerminatedNCT04867837Phase 3
• Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 InfectionCompletedNCT04651400
• Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency DiseasesActive, not recruitingNCT04640142Phase 3
• Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)CompletedNCT04502030Phase 3
• Effectiveness and Tolerability of Eqwilate in Real-life ConditionsActive, not recruitingNCT04106908
• Use of Fibryga, a Fibrinogen Concentrate in Real World: Retrospective Collection of Clinical DataCompletedNCT04106895
• Safety and Efficacy of Fibryga in Congenital Fibrinogen DeficiencyTerminatedNCT03793426
• Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune DiseasesTerminatedNCT03656640
• Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin DeficiencyWithdrawnNCT03385395Phase 2
• Observational Study of the Use of octaplasLG®.CompletedNCT03369314
• The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary ImmunodeficiencyCompletedNCT03369301
• Use of Prothrombin Complex Concentrate in Patients Admitted in Emergency Care Units for Severe Bleeding While Receiving Oral AnticoagulantsCompletedNCT03320603Not applicable
• A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid PushCompletedNCT02503293Phase 4
• Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or PumpsCompletedNCT02180763Phase 4
• Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver TransplantationTerminatedNCT02037373
• Octaplas Adult TTP TrialTerminatedNCT01938404
• Octagam 5% Versus Comparator Post Marketing TrialCompletedNCT01859754
• Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDPTerminatedNCT01225276Phase 2/3
• Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)TerminatedNCT00411801Phase 3

← Octapharma overview and focus areas